Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.84
-0.64 (-0.99%)
At close: Mar 28, 2025, 4:00 PM
63.00
-0.84 (-1.32%)
After-hours: Mar 28, 2025, 6:54 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$2,900,926
Profits / Employee
$1,268,831
Market Cap
7.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 350 | -23 | -6.17% |
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HALO News
- 9 days ago - Halozyme Joins the $1 Billion Club - FXEmpire
- 4 weeks ago - Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - PRNewsWire
- 5 weeks ago - Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS - PRNewsWire
- 7 weeks ago - Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - PRNewsWire
- 7 weeks ago - CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - PRNewsWire
- 2 months ago - Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PRNewsWire
- 2 months ago - Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - PRNewsWire